Industry/Regulatory Developments
Tesamorelin reduced liver fat in a defined HIV trial. The indication did not widen by itself.
Stanley and colleagues reported less visceral fat and less liver fat in a randomized trial. The approved use remained the lipodystrophy indication on the label.
After the pivotal visceral-fat trials, Stanley and colleagues asked a more specific metabolic question. In a randomized clinical trial published in JAMA in 2014, tesamorelin was given to adults with HIV and abdominal fat accumulation, and the investigators followed visceral adipose tissue and liver fat. The paper reports reductions in both, with glucose and HbA1c among the metabolic measures readers should inspect in the tables rather than in a paraphrase.
A positive trial is not an automatic new label
Drug indications change through supplements and reviews, not through a journal club. A liver-fat result in HIV-associated abdominal fat accumulation does not silently become an indication for fatty liver disease in people without HIV, and it does not become an indication for a research-supply tesamorelin vial. The Egrifta label remains the document that says what was approved. If that label has been revised since the 2010 PDF linked here, the current DailyMed or FDA record wins.
Why this sits in the regulatory section
It is a reminder about scope. Good trials accumulate. Approvals stay narrow until an agency says otherwise. Quoting the JAMA result next to a 10 mg or 20 mg catalog price would erase that distinction. This summary does not include a price or a product link. The DOI is the destination.